Dr. Garfall of the FDA Approval of Teclistamab in Relapsed/Refractory Multiple Myeloma
October 25th 2022Alfred L. Garfall, MD, discusses the significance of the FDA approval of teclistamab-cqyv in relapsed/refractory multiple myeloma and how this agent might fit into the treatment paradigm going forward.
Read More
Dr. Garfall on Quadruplet Regimen in Multiple Myeloma
November 20th 2019Alfred L. Garfall, MD, provides insight on the FDA approval of daratumumab added to bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Read More